WO2010095270A1 - 抗ヒトα9インテグリン抗体とその用途 - Google Patents
抗ヒトα9インテグリン抗体とその用途 Download PDFInfo
- Publication number
- WO2010095270A1 WO2010095270A1 PCT/JP2009/053218 JP2009053218W WO2010095270A1 WO 2010095270 A1 WO2010095270 A1 WO 2010095270A1 JP 2009053218 W JP2009053218 W JP 2009053218W WO 2010095270 A1 WO2010095270 A1 WO 2010095270A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human
- integrin
- antibody
- amino acid
- integrin antibody
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
Definitions
- the present invention relates to an anti-human ⁇ 9 integrin antibody and its use. More specifically, the present invention relates to a monoclonal antibody, a chimeric antibody, a humanized antibody and a human antibody that specifically recognize human ⁇ 9 integrin, a hybridoma cell that produces the monoclonal antibody, a method for producing the monoclonal antibody, and the hybridoma.
- the present invention relates to a method for producing cells, a therapeutic agent containing the anti-human ⁇ 9 integrin antibody, a diagnostic agent containing the human ⁇ 9 integrin antibody, a screening method for compounds that inhibit the activity of human ⁇ 9 integrin, and the like.
- integrin is composed of a 1: 1 heterodimer of ⁇ and ⁇ chains. To date, 18 types of ⁇ chains and 8 types of ⁇ chains have been discovered, and at least 24 types of these combinations have been identified and confirmed. . Each integrin is known to recognize a specific extracellular matrix (ligand).
- ligand extracellular matrix
- the role of transmembrane cell adhesion proteins including integrins is not only the adhesion and fixation of cells and extracellular matrix, but also converts information from extracellular matrix into intracellular signals, cell proliferation, movement, cell death, It has been elucidated that it plays a role in the regulation of differentiation.
- Integrins are classified into subfamilies based on their specificity and function for ligands.
- RGD receptors that recognize Arg-Gly-Asp (RGD) sequences contained in collagen receptors, laminin receptors, fibronectin, vitronectin, etc., only on leukocytes
- ⁇ 4 integrin and ⁇ 9 integrin are subfamilies that do not belong to any of these, and are called ⁇ 4 integrin subfamily.
- osteopontin As ligands that bind to ⁇ 4 and ⁇ 9 integrin, osteopontin (hereinafter abbreviated as OPN), EDA site of fibronectin, propeptide-von Willebrand factoc (pp-vWF), tissue type transglutaminase (tTG), The XIII blood coagulation factor and Vascular Ce11 Adhesion Molecule-1 (VCAM-1) are known. Further, as a ligand specifically recognized by ⁇ 4 integrin, CS-1 domain of fibronectin, MadCAM-1 ( ⁇ 4 ⁇ 7) and the like are known. On the other hand, tenascin C, plasmin and the like are known as ligands specifically recognized by ⁇ 9 integrin.
- OPN which is a kind of extracellular matrix (ECM)
- ECM extracellular matrix
- amino acid sequences of the ⁇ 4 and ⁇ 9 integrin and ⁇ 1 integrin subunits are known and registered in GenBank. These integrins are known to have high amino acid sequence similarity between species.
- WO 02/081522 discloses therapeutic effects on rheumatoid arthritis and hepatitis by suppressing OPN function using neutralizing antibodies against OPN-deficient mice and OPN.
- this publication discloses that the SVVYGLR sequence, which is a recognition sequence for ⁇ 4 integrin and ⁇ 9 integrin, is important for the onset of inflammatory diseases, and receptors for OPN are expressed in immunocompetent cells and the like. It is disclosed that WO02 / 081522
- Hybridoma cells (1K11, 21C5, 24I11, 25B6, and 28S1) were produced (FERM BP-10510, FERM BP-10511, FERM BP-10512, FERM BP-10513, and FERM BP-, respectively).
- the present invention provides the following anti-human ⁇ 9 integrin antibody, its monoclonal antibody, its production cell, a therapeutic agent containing the antibody, a screening method for a compound that inhibits ⁇ 9 integrin activity, and the like.
- An anti-human ⁇ 9 integrin antibody comprising any one of the amino acid sequences of SEQ ID NOs: 1 to 12.
- An anti-human ⁇ 9 integrin antibody containing the amino acid sequences of SEQ ID NOs: 2, 4, 6, 8, 10, and 12. (6) The amino acid sequence of any one of SEQ ID NOs: 1 to 6 as the amino acid sequence in the heavy chain complementarity determining region (CDRH), and the amino acid sequence of SEQ ID NOs: 7 to 12 as the amino acid sequence in the light chain complementarity determining region (CDRL). An anti-human ⁇ 9 integrin antibody containing any amino acid sequence. (7) The anti-human ⁇ 9 integrin antibody according to any one of the above (1) to (6), which inhibits binding between human ⁇ 9 integrin and a ligand of ⁇ 9 integrin.
- a therapeutic agent for cancer, inflammatory disease, infectious disease, autoimmune disease or bone disease comprising the anti-human ⁇ 9 integrin antibody according to any one of (1) to (12) as an active ingredient.
- Cancer, inflammatory disease, infectious disease, autoimmune disease or bone containing both the anti-human ⁇ 9 integrin antibody and anti-human ⁇ 4 integrin antibody according to any of (1) to (12) as active ingredients Therapeutic agent for diseases.
- the present invention provides a novel anti- ⁇ integrin antibody.
- the anti- ⁇ 9 integrin antibody of the present invention exhibits an excellent ⁇ 9 integrin function inhibitory action, and includes cancer (eg, proliferation and metastasis of cancer cells), inflammatory diseases (eg, rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, Cotton fibrosis, diabetes, arteriosclerosis, multiple sclerosis, inflammatory bowel disease (ulcerative colitis, Crohn's disease, etc.), infection (eg, hepatitis), autoimmune disease (eg, systemic lupus erythematosus, multiple It has therapeutic effects on myositis, autoimmune thyroid disease, tubulointerstitial nephritis, myasthenia gravis) and bone disease (for example, osteoporosis).
- cancer eg, proliferation and metastasis of cancer cells
- inflammatory diseases eg, rheumatoid arthritis,
- the pharmaceutical composition containing both the anti- ⁇ 9 integrin antibody and the anti- ⁇ 4 integrin antibody of the present invention has further improved therapeutic effects on cancer, inflammatory diseases and the like. Since the antibody of the present invention can detect the expression of ⁇ 9 integrin in cells and tissues pathologically, it can also be used as a diagnostic agent.
- Tysabri (natalizumab), an antibody against ⁇ 4 integrin, was launched in November 2004 as a treatment for multiple sclerosis by Biogen Idec Inc. (Massachusetts, USA) and Elan Corporation (Ireland). Approved by the US Food and Drug Administration (FDA). Tysabri (registered trademark) has been clinically developed for diseases such as Crohn's disease and rheumatoid arthritis. An anti-human ⁇ 4 ⁇ 1 integrin monoclonal antibody called P4C2 is used at the laboratory level.
- an antibody against ⁇ 9 integrin is a monoclonal antibody called Y9A2, which shows specificity for human and guinea pig ⁇ 9 integrin (A. Wang et al, (1996) Am. J. Respir., Ce11 Mol. Biol. 15, 664- 672) is provided for experimental use but is not used clinically.
- the present invention provides monoclonal antibodies against human ⁇ 9 integrin.
- the “antibody” refers to an entire antibody molecule or a fragment thereof that specifically binds to an antigen ⁇ 9 integrin or a partial peptide thereof (eg, a fragment such as Fab, Fab ′, F (ab ′) 2 ) which may be a polyclonal antibody or a monoclonal antibody.
- it means a monoclonal antibody.
- “antibody” includes chimeric antibodies, humanized antibodies, and human antibodies.
- an antibody “specifically binds" to a certain protein or fragment thereof means that the antibody is directed against a specific amino acid sequence of these proteins or fragments thereof, rather than its affinity for other amino acid sequences. Binding with substantially high affinity.
- substantially high affinity means high affinity that allows the specific amino acid sequence to be detected separately from other amino acid sequences by a desired measuring apparatus or method.
- the coupling constant (K a ) is at least 10 7 M ⁇ 1 , preferably at least 10 8 M ⁇ 1 , more preferably 10 9 M ⁇ 1 , even more preferably 10 10 M ⁇ 1 , It means a binding affinity such as 10 11 M ⁇ 1 , 10 12 M ⁇ 1 or higher, for example up to 10 13 M ⁇ 1 or higher.
- the “monoclonal antibody” refers to one that is highly specific for an antigen and recognizes a single antigen.
- antibody fragment refers to a part of a full-length antibody, and is an antigen-binding region or a variable region.
- antibody fragments include Fab, Fab ′, F (ab ′) 2 , and Fv fragments. These antibody fragments can be prepared by generally known methods such as papain digestion and pepsin digestion of antibodies.
- chimeric antibody is a human / mouse chimeric antibody obtained by genetically modifying the constant region of the anti-human ⁇ 9 integrin antibody obtained in the present invention so as to have the same constant region as that of a human antibody (European Patent Publication) Gazette EP0125023).
- “Humanized antibody” means that the primary structure of the anti-human ⁇ 9 integrin antibody obtained in the present invention other than the complementary recognition region (CDR) of the H chain and L chain is genetically engineered to a primary structure corresponding to a human antibody. Refers to a modified antibody.
- Human antibody means a monoclonal antibody (see European Patent Publication EP0546073) prepared using a transgenic animal into which a gene involved in human antibody production has been introduced.
- the present invention first provides an anti-human ⁇ 9 integrin antibody different from the anti-human ⁇ 9 integrin antibody produced so far.
- An antibody according to a preferred embodiment of the invention contains the amino acid sequence of SEQ ID NO: 1, 3, 5, 7, 9, or 11.
- Further preferred antibodies include 2 or more, 3 or more, 4 or more, 5 or more, or 6 amino acid sequences selected from the group consisting of the amino acid sequences of SEQ ID NOs: 1, 3, 5, 7, 9, and 11.
- Anti-human ⁇ 9 integrin antibody is provided.
- an antibody according to another aspect of the present invention contains the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 10, or 12.
- Further preferred antibodies are 2 or more, 3 or more, 4 or more, 5 or more, or 6 amino acid sequences selected from the group consisting of the amino acid sequences of SEQ ID NOs: 2, 4, 6, 8, 10, and 12.
- Anti-human ⁇ 9 integrin antibody is provided.
- a particularly preferred antibody in the present invention is an anti-human ⁇ 9 integrin antibody produced by a hybridoma cell indicated by accession number FERM BP-10830 or FERM BP-10831.
- the ⁇ 9 integrin used as an antigen in the present invention is (1) a protein derived from any cell expressing human or other mammalian ⁇ 9 integrin, or any tissue in which those cells exist, and (2) encoding ⁇ 9 integrin. It may be a recombinant protein in which a genetic DNA, preferably cDNA, is introduced and expressed in a cell line such as a bacterium, yeast or animal cell, or (3) a synthetic protein.
- the ⁇ 9 integrin of the present invention also includes polypeptides having substantially the same amino acid sequence as the amino acid sequence of ⁇ 9 integrin of various mammals, particularly preferably the amino acid sequence of human ⁇ 9 integrin (SEQ ID NO: 13).
- polypeptide having substantially the same amino acid sequence means that a natural ⁇ 9 integrin, particularly preferably a human-derived ⁇ 9 integrin, has a biological property substantially equivalent to that in the amino acid sequence.
- a plurality of amino acids preferably 1 to 10 amino acids, particularly preferably 1 to several (eg, 1 to 5, 1 to 4, 1 to 3, 1 to 2) amino acids are substituted.
- a plurality of amino acids preferably 1 to 10 Mutation having an amino acid sequence to which one amino acid, particularly preferably 1 to several (for example, 1 to 5, 1 to 4, 1 to 3, 1 to 2) amino acids are added It means Ripepuchido. Further, it may be a mutant polypeptide having a plurality of such substitutions, deletions, modifications, and additions.
- the ⁇ 9 integrin of the present invention can be obtained by appropriately using a method known in the art such as a chemical synthesis method, a cell culture method, or a modification method thereof, in addition to a gene recombination technique. Can be manufactured.
- a method for producing a mutant polypeptide for example, a synthetic oligonucleotide site mutation introduction method (gapped duplex method), a method of randomly introducing point mutations by nitrite or sulfite treatment, a deletion mutation by Ba131 enzyme, etc.
- a method for preparing a body for example, a cassette mutation method, a linker scanning method, a misincorporation method, a mismatch primer method, a DNA segment synthesis method, and the like.
- the ⁇ 9 integrin of the present invention also includes “a part” of the ⁇ 9 integrin.
- the “part” refers to a part including a region necessary for binding to an ⁇ 9 integrin ligand such as OPN, tenascin C, VCAM-1.
- the “part” of the ⁇ 9 integrin can be produced by a gene recombination technique or a chemical synthesis method according to a method known in the technical field described later or a modification method thereof, or has been isolated by a cell culture method. It can be produced by appropriately cleaving ⁇ 9 integrin, particularly preferably human-derived ⁇ 9 integrin, with a proteolytic enzyme or the like.
- the cell itself overexpressing ⁇ 9 integrin on the cell membrane by a recombinant technique, or a membrane fraction thereof can be used.
- the ⁇ 9 integrin of the present invention includes a polypeptide having an amino acid sequence substantially identical to the amino acid sequence of human ⁇ 9 integrin (SEQ ID NO: 13).
- a cell itself that overexpresses human ⁇ 9 integrin on a cell membrane by a recombinant technique is preferably used. Therefore, a gene encoding human ⁇ 9 integrin (for example, cDNA) as described later is cloned using a known genetic engineering technique, and the cell itself overexpressing human ⁇ 9 integrin on the cell membrane, or a cell membrane fraction thereof, is cloned. It may be prepared as an antigen.
- the antigen is administered to the animal to be immunized per se, together with a carrier or diluent, at a site where antibody production is possible by administration.
- Complete Freund's adjuvant or incomplete Freund's adjuvant may be administered in order to enhance antibody production ability upon administration.
- the administration is usually performed once every 1 to 6 weeks, about 2 to 10 times in total.
- Examples of the warm-blooded animal to be used include mice, monkeys, rabbits, dogs, guinea pigs, rats, hamsters, sheep, goats, chickens and the like. In the present invention, mice are preferably used.
- the subject of treatment is a human and the ⁇ 9 integrin-inhibiting antibody-producing animal is a mouse
- myeloma cell a cell derived from mouse, rat, human or the like is used. Examples include mouse myeloma P3U1, P3X63-Ag8, P3X63-Ag8-U1, P3NS1-Ag4, SP2 / 0-Ag14, and P3X63-Ag8-653.
- Antibody-producing cells and myeloma cells are the same species, particularly the same strain. It is preferably derived from an animal.
- Myeloma cells can be stored frozen or passaged and maintained in a common medium supplemented with horse, rabbit or fetal calf serum. For cell fusion, cells in the logarithmic growth phase are preferably used.
- P3X63-Ag8-653 is preferably used.
- Examples of methods for forming hybridomas by fusing antibody-producing cells and myeloma cells include a method using polyethylene glycol (PEG), a method using Sendai virus, and a method using an electrofusion device.
- PEG polyethylene glycol
- spleen cells and myeloma cells are placed in an appropriate medium or buffer containing about 30 to 60% PEG (average molecular weight 1000 to 6000) at 1 to 10: 1, preferably 5 to 10: 1.
- the suspension may be suspended at a mixing ratio and allowed to react for about 30 seconds to 3 minutes under conditions of a temperature of about 25 to 37 ° C. and a pH of 6 to 8. After completion of the reaction, the PEG solution is removed and the suspension is resuspended in a culture medium and seeded in a cell well plate to continue the culture.
- selection of hybridoma cells Selection of hybridoma cells producing a monoclonal antibody can be performed according to a known or similar method. Usually, it can be performed in a medium for animal cells supplemented with HAT (hypoxanthine, aminopterin, thymidine).
- HAT hyperxanthine, aminopterin, thymidine
- any medium can be used as long as it can grow hybridoma cells.
- RPMI 1640 medium containing 1-20%, preferably 10-20% fetal bovine serum, GIT medium (Wako Pure Chemical Industries, Ltd.) containing 1-10% fetal bovine serum, or serum-free for hybridoma culture A medium (SFM-101, Nissui Pharmaceutical Co., Ltd.) or the like can be used.
- the culture temperature is usually 20 to 40 ° C., preferably about 37 ° C.
- the culture time is usually 5 days to 3 weeks, preferably 1 week to 2 weeks. Culturing can usually be performed under
- the production of the monoclonal antibody of the present invention can be confirmed and screened by using the cell ELISA method described in New Clinical Immunization Experimental Procedure (part 3), Scientific Review, 1997.
- cells used for immunization are expected to have a high background and a large number of false positives when used for screening, they react with human ⁇ 9 integrin that is overexpressed in cells other than those used for immunization, A clone that does not react with cells overexpressing human ⁇ 4 integrin can be used as an anti-human ⁇ 9 integrin antibody.
- Monoclonal antibodies can be prepared from such clones by repeating the limiting dilution method 1 to 5 times, preferably 2 to 4 times.
- the obtained antibody can be purified to homogeneity.
- separation and purification methods used for ordinary proteins may be used.
- antibodies can be separated and purified by appropriately selecting and combining chromatography columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing etc. (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988), but is not limited thereto.
- columns used for affinity chromatography include a protein A column and a protein G column.
- Hyper D, POROS, Sepharose FF (Amersham Biosciences) etc. are mentioned as a column using a protein A column.
- the obtained antibody can be variously labeled using a known method or a commercially available kit (for example, biotin label, FITC label, APC label).
- biotin labeling using Biotin Labeling Kit (Dojindo Laboratories) is preferably used.
- the monoclonal antibody thus obtained can be purified as necessary and then formulated according to a conventional method, and used as a preventive and / or therapeutic agent for cancer, inflammatory diseases, infectious diseases, autoimmune diseases, bone diseases and the like. it can.
- These dosage forms as prophylactic and / or therapeutic agents can be parenteral preparations such as injections and infusions, and can be used as oral preparations by ingenuity.
- carriers, diluents, or additives suitable for the dosage form can be used within the pharmacologically and pharmaceutically acceptable range.
- integrins The role of integrins is not only the adhesion and fixation of cells and extracellular matrix (ECM), but also converts information from the extracellular matrix into intracellular signals and regulates cell proliferation, movement, cell death, differentiation, etc. It has been elucidated. Therefore, the obtained monoclonal antibody can block the intracellular signal transmission of information from the ECM by inhibiting the binding between the ECM and ⁇ 9 integrin, so that it is possible to treat a disease involving ECM.
- ECM that binds to ⁇ 9 integrin, and OPN, fibronectin, propeptide-von Willebrand facco (pp-vWF), tissue type transglutaminase (tTG), XIII blood coagulation factor, Vascular Ce11 Adhesion Molecule-1 (VCAM-1), tenascin C, plasmin and the like are known.
- OPN fibronectin
- tTG tissue type transglutaminase
- tTG tissue type transglutaminase
- XIII blood coagulation factor XIII blood coagulation factor
- VCAM-1 Vascular Ce11 Adhesion Molecule-1
- tenascin C plasmin and the like
- Preparations comprising the antibody of the present invention (particularly, monoclonal antibody) as an active ingredient are cancer (eg, proliferation and metastasis of cancer cells), inflammatory diseases (eg, rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, cotton fibrosis) , Diabetes, arteriosclerosis, multiple sclerosis, inflammatory bowel disease (ulcerative colitis, Crohn's disease)), infection (eg hepatitis), autoimmune disease (eg systemic lupus erythematosus, polymyositis, autoimmune thyroid) It can be used as a therapeutic agent or prophylactic agent for diseases, tubulointerstitial nephritis, myasthenia gravis) and bone diseases (eg osteoporosis).
- cancer eg, proliferation and metastasis of cancer cells
- inflammatory diseases eg, rheumatoid arthritis, osteoarthritis, hepatitis, bronchi
- the dose varies depending on the administration subject, target disease, symptom, administration route, etc.
- the antibody of the present invention is usually used as a single dose.
- the dose or the number of administrations may be increased according to the symptoms.
- the antibody of the present invention can be administered per se or as an appropriate pharmaceutical composition.
- the pharmaceutical composition used for the administration comprises the antibody or a salt thereof and a pharmacologically acceptable carrier, diluent or excipient.
- Such compositions are provided as parenteral or oral dosage forms.
- injections for example, injections, nasal drops, suppositories and the like are used, and injections are intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, infusions, and the like. Includes dosage forms such as injections.
- Such an injection is prepared according to a known method, for example, by dissolving, suspending or emulsifying the above antibody in a sterile aqueous or oily liquid usually used for injection.
- aqueous solution for injection for example, isotonic solution containing physiological saline, glucose, sucrose, mannitol, and other adjuvants is used, and a suitable solubilizer such as alcohol (eg, ethanol), Polyalcohols (eg, propylene glycol, polyethylene glycol), nonionic surfactants (eg, polysorbate 80, polysorbate 20, HCO-50 (polyoxyethylene (50 mol) additive of hydrogenated castor oil)) and the like may be used in combination.
- alcohol eg, ethanol
- Polyalcohols eg, propylene glycol, polyethylene glycol
- nonionic surfactants eg, polysorbate 80, polysorbate 20, HCO-50 (polyoxyethylene (50 mol) additive of hydrogenated castor oil)
- oily liquid for example, sesame oil, soybean oil and the like are used, and benzyl benzoate, benzyl alcohol and the like may be used in combination as a solubilizing agent
- the prepared injection solution is usually filled in appropriate ampules, vials, and syringes.
- a suppository used for rectal administration is prepared by mixing the above-mentioned antibody into a usual nasal base or suppository base.
- a lyophilized preparation can be prepared by adding an appropriate excipient to the above antibody, and dissolved in water for injection or physiological saline at the time of use to obtain an injection solution.
- oral administration of a protein such as an antibody is difficult because it is degraded by the digestive tract, but there is a possibility of oral administration depending on the ingenuity of the antibody fragment or modified antibody fragment and the dosage form.
- the above parenteral pharmaceutical composition is preferably prepared in a dosage unit form suitable for the dose of the active ingredient.
- dosage form of such a dosage unit include injections (ampoules, vials, prefilled syringes), nasal drops, suppositories, etc., and usually 5 to 500 mg per dosage unit dosage form, especially for injections It is preferable that 5 to 100 mg of the antibody described above is contained in other dosage forms.
- compositions may contain other active ingredients as long as an undesirable interaction is not caused by blending with the antibody.
- the pharmaceutical preparation of the present invention can contain an anti-human ⁇ 4 integrin antibody in addition to the above antibody.
- the mixing ratio is not particularly limited.
- the ratio of anti-human ⁇ 9 integrin antibody: anti-human ⁇ 4 integrin antibody can be adjusted within a range of 1 to 99:99 to 1.
- the pharmaceutical composition comprising the monoclonal antibody of the present invention is a diagnostic agent for inflammatory diseases such as rheumatoid arthritis, hepatitis, bronchial asthma, fibrosis, diabetes, cancer metastasis, arteriosclerosis, multiple sclerosis, granulomas, etc.
- inflammatory diseases such as rheumatoid arthritis, hepatitis, bronchial asthma, fibrosis, diabetes, cancer metastasis, arteriosclerosis, multiple sclerosis, granulomas, etc.
- autoimmune diseases such as suppression of chronic rejection after organ transplantation, systemic autoimmune disease, lupus erythematosus, uveitis, Behcet's disease, polymyositis, filamentous proliferative nephritis, sarcoidosis, etc.
- the monoclonal antibody of the present invention can specifically recognize ⁇ 9 integrin, it is used for quantification of ⁇ 9 integrin in a test solution, particularly quantification by sandwich immunoassay, competition method, immunometric method, or the like. be able to.
- sandwich immunoassay particularly quantification by sandwich immunoassay, competition method, immunometric method, or the like.
- immunometric method or the like.
- a measurement system may be constructed by adding ordinary technical considerations of those skilled in the art to the usual conditions and operation methods in each method. For details of these general technical means, it is possible to refer to reviews, books and the like.
- ⁇ 9 integrin can be quantified with high sensitivity by using the antibody of the present invention.
- various diseases associated with ⁇ 9 integrin can be diagnosed by utilizing the in vivo ⁇ 9 integrin quantification method using the antibody of the present invention. For example, when an increase or decrease in the concentration of ⁇ 9 integrin is detected, it can be diagnosed that the disease is likely to be related to ⁇ 9 integrin, for example, an inflammatory disease or likely to be affected in the future.
- the monoclonal antibody of the present invention can be used for specifically detecting ⁇ 9 integrin present in a subject such as a body fluid or tissue. Moreover, it can be used for preparation of an antibody column used for purifying ⁇ 9 integrin, detection of ⁇ 9 integrin contained in each fraction during purification, analysis of behavior of ⁇ 9 integrin in a test cell, and the like.
- a compound that inhibits the activity of human ⁇ 9 integrin can be screened using the epitope on human ⁇ 9 integrin recognized by the antibody of the present invention.
- the present invention uses a peptide containing the amino acid sequence of human ⁇ 9 integrin (hereinafter referred to as “peptide A”), and a method for screening a low molecular weight compound that inhibits the activity of human ⁇ 9 integrin I will provide a.
- peptide A and a human ⁇ 9 integrin ligand for example, tenascin C, plasmin, etc.
- a human ⁇ 9 integrin ligand for example, tenascin C, plasmin, etc.
- the comparison between the steps (i) and (ii) is performed, for example, by measuring the amount of ligand binding to peptide A.
- the candidate compound obtained by such a method is subjected to an experiment for confirming whether to inhibit the activity of human ⁇ 9 integrin to obtain a compound that inhibits the activity of human ⁇ 9 integrin.
- polypeptides, proteins, biologically derived non-peptidic compounds, synthetic compounds, microbial cultures, cell extracts, plant extracts, animal tissue extracts, etc. can be used as test substances.
- a known compound may be used.
- the selected compound can be used as a prophylactic and / or therapeutic agent for cancer, inflammatory diseases, infectious diseases, autoimmune diseases, bone diseases and the like, like the antibody of the present invention.
- Example 1 [Preparation of antibodies against human ⁇ 9 integrin]
- human ⁇ 9 integrin-expressing cells human ⁇ 9 / NIH-3T3 cells
- human ⁇ 9 / NIH-3T3 cells were intraperitoneally administered at 3 ⁇ 10 6 cells / mouse, and one week and two weeks later, human ⁇ 9 / NIH-3T3 cells were treated 3 ⁇ 10 6 cells / mouse were administered intraperitoneally.
- human ⁇ 9 / NIH-3T3 cells were intravenously administered at 2 ⁇ 10 6 cells / mouse.
- a clone that reacts with human ⁇ 9 / CHO-K1 cells and a human melanoma cell line (G361 cell) that endogenously expresses human ⁇ 9 integrin and does not react with human ⁇ 4 integrin-expressing CHO-K1 cells was defined as an anti- ⁇ 9 integrin antibody.
- G361 cell human melanoma cell line
- 2 hybridoma cell clones (K33N, M35A) producing anti-human ⁇ 9 integrin antibody were established.
- hybridoma cells K33N and M35A obtained here were deposited on May 29, 2007, 1-1-1 Higashi 1-chome, Tsukuba, Ibaraki, Chuo No. 6 (zip code 305-8666), National Institute of Advanced Industrial Science and Technology, Patent Biological Deposit Deposited at the center as deposit numbers FERM BP-10830 and FERM BP-10831, respectively.
- Example 2 [Analysis of complementary recognition region (CDR) of anti-human ⁇ 9 integrin antibody] MRNA was extracted from the hybridoma producing the human ⁇ 9 integrin antibody (K33N, M35A), and cDNA was prepared by reverse transcription. Using this cDNA as a template, PCR was performed using primers for ScFv cloning (Light Primer Mix, Heavy Primer Mix; Amersham Biosciences) to extend and amplify the variable regions of the antibody heavy chain and light chain, respectively. Next, the PCR product was incorporated into pCRII TOPO vector based on a conventional method. This was sequenced to determine the amino acid sequence. The above operation was performed three times for each antibody.
- ScFv cloning Light Primer Mix, Heavy Primer Mix; Amersham Biosciences
- amino acid sequences of the variable and CDR regions of the heavy and light chains of K33N and M35A were as shown in FIGS. 1A and 1B.
- amino acid sequence of the CDR region is as follows.
- K33N SYYMN (SEQ ID NO: 1)
- M35A SYWIH (SEQ ID NO: 2)
- K33N WIFPGSGNTKYNEKFKGK (SEQ ID NO: 3)
- M35A EINPSSGRTNFIENFETK (SEQ ID NO: 4)
- CDRH3 K33N: SWVSYGERYYFDY (SEQ ID NO: 5)
- K33N RASENYYSLA (SEQ ID NO: 7)
- M35A RASETVDSYGNTFMH (SEQ ID NO: 8)
- K33N NNSLED (SEQ ID NO: 9)
- M35A LASNLES (SEQ ID NO: 10)
- K33N KQAYDVPYT (SEQ ID NO: 11)
- M35A QQNNEDPYT (SEQ ID NO: 12)
- 1A and 1B also show sequences (JN Bio and Takara) obtained using an analysis method (different sequence analysis software) different from the sequence analysis method (GTS) described above. Details of each method are as follows.
- Hybridoma cells (K33N) were grown in TIL Media I medium (Immunobiological Laboratories) containing 10% fetal bovine serum (FBS; HyClone) at 7.5% CO 2 and 37 ° C. to proliferate.
- Total RNA was extracted from about 3 ⁇ 10 6 hybridoma cells using TRIzol reagent (Invitrogen) according to the Invitrogen protocol.
- the cDNA was prepared by reverse transcription using an oligo dT-primer using GeneRacer Kit (Invitrogen) and following the Invitrogen protocol.
- variable region cDNA of H chain and L chain uses 3 ′ primer corresponding to mouse constant regions ⁇ 1 and ⁇ , respectively, and GeneRacer 5 ′ primer (5′-CGACTGGAGCACGAGGACACTGA-3 ′ (SEQ ID NO: 14)) attached to GeneRacer Kit, Amplification was performed by PCR using Phusion DNA polymerase (New England Biolabs).
- the 3 ′ primaer for PCR amplification of the heavy chain variable region (VH) is 5′-GCCAGTGGATAGACAGATGG-3 ′ (SEQ ID NO: 15).
- the 3 ′ primer for PCR amplification of the L chain variable region (VL) is 5′-GATGGATACAGTTGGTGCAGC-3 ′ (SEQ ID NO: 16). Amplified VH and VL cDNAs were subcloned in pCR4Blunt-TOPO vector (Invitrogen) for sequencing. DNA sequence analysis of the variable region was performed at Tocore (Menlo Park).
- RNA of the cells was extracted by the Acid Guanidine-Phenol-Chloroform method (AGPC method) using RNAiso (Takara Bio Inc.).
- AGPC method Acid Guanidine-Phenol-Chloroform method
- the extracted RNA was treated with DNase I by a conventional method, then treated with phenol chloroform to remove DNase I, and purified by ethanol precipitation.
- the obtained RNA was suspended again in distilled water and used for analysis.
- reverse transcription reaction was performed with reverse transcriptase M-MLV (RNase H free) using Random Primer (9mer).
- PCR amplification of the variable region a part of each reverse transcription reaction solution is used as a template, the heavy chain primer Primer 1 and Heavy Primer 2 (Amersham Biosciences), and the light chain primer Light Primer Mix (Amersham Bioscience). Takara TaKaRa LA Taq was used as the PCR enzyme.
- the DNA fragment obtained by PCR was electrophoresed on an agarose gel, the band was cut out, and the gel was dissolved to purify the DNA.
- the purified DNA was TA cloned into pMD20-T vector.
- the gene sequence was determined using the M13-47 primer sequence contained in pMD20-T vector.
- the sequencing reaction was carried out using ABI 3730 sequencer (Applied Biosystems) according to the protocol of BigDye® Terminators® v3.1 “cyclesequencing” kit (Applied Biosystems).
- Example 3 Cell adhesion inhibitory effect of anti-human ⁇ 9 integrin antibody
- ECM extracellular matrix
- the OPN peptide is an SVVYGLR peptide conjugated with BSA (bovine serum albumin), TN-C fn3 (RAA) is a protein expressed by the third region of human tenascin-C fibrinctin Type III repeat in R. coli (RGD within this region). The sequence was converted to an RAA sequence).
- BSA bovine serum albumin
- RAA TN-C fn3
- the OPN peptide or tenascin-C fragment (TN-C fn3 (RAA)) was left in a 96-well plate at 37 ° C. for 1 hour and then blocked with 0.5% BSA / PBS.
- Human melanoma cells G361 were adjusted with 0.25% BSA / DMEM medium to 1 ⁇ 10 5 cells / mL, and each concentration of anti-human ⁇ 9 integrin antibody was added.
- G361 cells to which the antibody had been added were placed in a 96-well plate on which 200 ⁇ L each was solid-phased and reacted at 37 ° C. for 1 hour.
- FIG. 2 shows the effect of the anti-human ⁇ 9 integrin antibody on the adhesion of G361 cells to the OPN peptide
- FIG. 3 shows the result with the tenascin C fragment.
- M35A In the adhesion of G361 cells to the OPN peptide, M35A was less effective in inhibiting cell adhesion, similar to the negative subject 5A1 and the positive subjects 1K11, 25B6, 28S1. On the other hand, K33N inhibited cell adhesion in a small amount as compared with positive subjects 21C5 and 24I11, and showed cell adhesion inhibitory effect equivalent to Y9A2. In the adhesion of G361 cells to the tenascin-C fragment, M35A was less effective in inhibiting cell adhesion, but K33N inhibited cell adhesion in a small amount, and the same effect as that of Y9A2 was observed in positive subjects 21C5 and 24I11. It was clearly stronger than that. Thus, in particular, K33N showed a particularly remarkable cell adhesion inhibitory effect even when compared with other antibodies.
- Example 4 Comparison in recognition site of anti-human ⁇ 9 integrin antibody
- the cell adhesion inhibitory effect of the newly prepared anti-human ⁇ 9 integrin antibody K33N showed the same behavior as Y9A2
- FACS Fluorescence Activated Cell Sorting
- Streptavidin-labeled APC (0.5 ⁇ g / mL, 100 ⁇ L) was added to the cell solution, reacted at (4 ° C., 20 minutes), washed again with FACS buffer, and then 7-AAD (0.05 mg / mL, 20 ⁇ L) was used to stain dead cells. Thereafter, the cells were washed again with FACS buffer, and the cells were measured by FACS.
- the anti- ⁇ 9 integrin antibody of the present invention exhibits an excellent ⁇ 9 integrin function inhibitory action, and includes cancer (eg, proliferation and metastasis of cancer cells), inflammatory diseases (eg, rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, Cotton fibrosis, diabetes, arteriosclerosis, multiple sclerosis, inflammatory bowel disease (ulcerative colitis, Crohn's disease, etc.), infection (eg, hepatitis), autoimmune disease (eg, systemic lupus erythematosus, multiple It has therapeutic effects on myositis, autoimmune thyroid disease, tubulointerstitial nephritis, myasthenia gravis) and bone disease (for example, osteoporosis).
- cancer eg, proliferation and metastasis of cancer cells
- inflammatory diseases eg, rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma,
- the pharmaceutical composition containing both the anti- ⁇ 9 integrin antibody and the anti- ⁇ 4 integrin antibody of the present invention has further improved therapeutic effects on cancer, inflammatory diseases and the like. Since the antibody of the present invention can detect the expression of ⁇ 9 integrin in cells and tissues pathologically, it can also be used as a diagnostic agent.
- the anti-human ⁇ 9 integrin antibody (2 clones of the present invention (K33N, M35A), 5 other clones (1K11, 21C5, 24I11, 25B6, 28S1), and Y9A2) was compared with the cell adhesion inhibitory effect of human ⁇ 9 integrin-expressing cells (human melanoma) It is a figure which shows the result investigated by (alpha) 9 integrin binding site peptide (SVVYGLR) of cell G361) and OPN. As a negative control, a monoclonal antibody (5A1) against human osteopontin was used.
- the anti-human ⁇ 9 integrin antibody (2 clones of the present invention (K33N, M35A), 5 other clones (1K11, 21C5, 24I11, 25B6, 28S1), and Y9A2) was compared with the cell adhesion inhibitory effect of human ⁇ 9 integrin-expressing cells (human melanoma) It is a figure which shows the result investigated by (alpha) 9 integrin binding site peptide of the cell G361) and tenascin C fragment. As a negative control, a monoclonal antibody (5A1) against human osteopontin was used. It is a figure which shows the result of having investigated the competitive reaction of the novel anti-human alpha9 integrin antibody (K33N) and Y9A2 with respect to the human alpha9 integrin expression cell.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
(1)配列番号1~12のうちのいずれかのアミノ酸配列を含有する、抗ヒトα9インテグリン抗体。
(2)配列番号1、3、5、7、9、または11のアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
(3)配列番号1、3、5、7、9、および11のアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
(4)配列番号2、4、6、8、10、または12のアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
(5)配列番号2、4、6、8、10、および12のアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
(6)重鎖の相補性決定領域(CDRH)におけるアミノ酸配列として配列番号1~6のいずれかのアミノ酸配列を、軽鎖の相補性決定領域(CDRL)におけるアミノ酸配列として配列番号7~12のいずれかのアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
(7)ヒトα9インテグリンと、α9インテグリンのリガンドとの結合を阻害する、上記(1)~(6)のいずれかに記載の抗ヒトα9インテグリン抗体。
(8)モノクローナル抗体である、上記(1)~(7)のいずれかに記載の抗ヒトα9インテグリン抗体。
(9)キメラ抗体である、上記(1)~(8)のいずれかに記載の抗ヒトα9インテグリン抗体。
(10)ヒト化抗体である、上記(1)~(8)のいずれかに記載の抗ヒトα9インテグリン抗体。
(11)ヒト抗体である、上記(1)~(8)のいずれかに記載の抗ヒトα9インテグリン抗体。
(12)受託番号FERM BP-10830またはFERM BP-10831で標示されるハイブリドーマ細胞により産生される抗ヒトα9インテグリン抗体。
(13)上記(1)~(12)のいずれかに記載の抗ヒトα9インテグリン抗体を有効成分として含む、癌、炎症性疾患、感染症、自己免疫疾患または骨疾患の治療剤。
(14)上記(1)~(12)のいずれかに記載の抗ヒトα9インテグリン抗体および抗ヒトα4インテグリン抗体の両方を有効成分として含む、癌、炎症性疾患、感染症、自己免疫疾患または骨疾患の治療剤。
(15)上記(1)~(12)のいずれかに記載の抗ヒトα9インテグリン抗体を有効成分として含む、癌、炎症性疾患、感染症、自己免疫疾患または骨疾患の診断剤。
(16)上記(1)~(12)のいずれかに記載の抗ヒトαインテグリン抗体を産生する細胞。
(17)受託番号FERM BP-10830またはFERM BP-10831で標示されるハイブリドーマ細胞。
(18)α9インテグリンのアミノ酸配列を含有するペプチドを用いることを特徴とする、α9インテグリンの活性を阻害する化合物のスクリーニング方法。
α4インテグリンに対する抗体であるTysabri(登録商標)(natalizumab)は2004年11月にバイオジェン・アイデック(Biogen Idec Inc.、米マサチューセッツ州)とエラン(Elan Corporation、アイルランド)が多発性硬化症治療薬として米食品医薬品局(FDA)から承認を受けている。また、Tysabri(登録商標)はクローン病、リウマチ様関節炎等の疾患を対象として臨床開発されている。なお、P4C2という抗ヒトα4β1インテグリン・モノクローナル抗体が実験室レベルで用いられている。
α9インテグリンに対する抗体を作製するために、マウス線維芽細胞であるNIH-3T3細胞へ遺伝子導入を行い、ヒトα9インテグリンを過剰発現する細胞株を樹立し、この細胞を抗原としてマウスに免疫した。
細胞融合で得られた種々のハイブリドーマからヒトα9インテグリンのみに反応するクローンを効率よく得るために、同じインテグリンファミリーであるヒトα4インテグリンをCHO-K1細胞に発現させた細胞を用いて他のインテグリンとは交差反応性を示さず、親細胞(CHO-K1)の細胞表面抗原とは反応しないクローンを選抜することにより、効率的にヒトα9インテグリンに特異的に反応する阻害抗体を得た。
本発明は、ヒトα9インテグリンに対するモノクローナル抗体を提供する。本発明において、「抗体」とは、抗原であるα9インテグリンまたはその部分ペプチドに特異的に結合する抗体分子全体またはその断片(例えば、Fab、Fab′、F(ab′)2、などの断片)を意味し、ポリクローナル抗体であってもモノクローナル抗体であってもよい。好ましくは、本発明においてはモノクローナル抗体を意味する。また、本発明において「抗体」は、キメラ抗体、ヒト化抗体、ヒト抗体を包含する。
[α9インテグリン(抗原)]
抗原は、免疫される動物に対して投与により抗体産生が可能な部位にそれ自体あるいは担体、希釈剤とともに投与される。投与に際して抗体産生能を高めるため、完全フロイントアジュバントや不完全フロイントアジュバントを投与してもよい。投与は通常1~6週毎に1回ずつ、計2~10回程度行われる。用いられる温血動物としては、例えば、マウス、サル、ウサギ、イヌ、モルモット、ラット、ハムスター、ヒツジ、ヤギ、ニワトリ等が挙げられるが、本発明ではマウスが好適に用いられる。
[抗体産生細胞とミエローマ細胞との細胞融合]
モノクローナル抗体を産生するハイブリドーマ細胞の選別は、公知あるいはそれに準じる方法に従って行なうことができる。通常、HAT(ヒポキサンチン、アミノプテリン、チミジン)を添加した動物細胞用培地で行なうことができる。選別および育種用培地としては、ハイブリドーマ細胞が生育できるものならばどのような培地を用いても良い。例えば、1~20%、好ましくは10~20%の牛胎児血清を含むRPMI 1640培地、1~10%の牛胎児血清を含むGIT培地(和光純薬工業(株))あるいはハイブリドーマ培養用無血清培地(SFM-101、日水製薬(株))などを用いることができる。培養温度は、通常20~40℃、好ましくは約37℃である。培養時間は、通常、5日~3週間、好ましくは1週間~2週間である。培養は、通常5%CO2下で行なうことができる。
得られた抗体は、均一にまで精製することができる。抗体の分離、精製は通常のタンパク質で使用されている分離、精製方法を使用すればよい。例えばアフィニティークロマトグラフィー等のクロマトグラフィーカラム、フィルター、限外濾過、塩析、透析、SDSポリアクリルアミドゲル電気泳動、等電点電気泳動等を適宜選択、組み合わせれば、抗体を分離、精製することができる(Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988)が、これらに限定されるものではない。アフィニティークロマトグラフィーに用いるカラムとしては、プロテインAカラム、プロテインGカラムが挙げられる。例えばプロテインAカラムを用いたカラムとして、Hyper D, POROS, Sepharose F. F.(Amersham Biosciences)等が挙げられる。
得られた抗体を、公知の方法または市販のキットを用いて各種標識化(例えば、ビオチン標識、FITC標識、APC標識)できる。本発明では、Biotin Labeling Kit(同仁化学)を用いたビオチン標識が好適に用いられる。
インテグリンの役割は、細胞と細胞外マトリックス(ECM)の接着、固定のみならず、細胞外マトリックスからの情報を細胞内シグナルに変換し、細胞の増殖、運動、細胞死、分化などの調節を担っていることが解明されてきている。従って、得られたモノクローナル抗体は、ECMとα9インテグリンとの結合を阻害することにより、ECMからの情報の細胞内シグナル伝達を遮断できることから、ECMが関与する疾患の治療が可能である。α9インテグリンに結合するECM、およびα9リガンドとしてOPN、ファイブロネクチン、プロペプチド-フォンビルブラントファククー(pp-vWF)、組織型トランスグルタミナーゼ(tTG)、第XIII血液凝固因子、Vascular Ce11 Adhesion Molecule-1(VCAM-1)、テネイシンC、プラスミンなどが知られている。これらのECMとα9インテグリンを発現している細胞や癌細胞を用い、得られたモノクローナル抗体の存在下での結合阻害をin vitroで観察することにより、本発明のモノクローナル抗体の対象疾患を見出すことができる。
本発明の抗体(特に、モノクローナル抗体)を有効成分とする製剤は、癌(例えば癌細胞の増殖、転移)、炎症性疾患(例えば関節リウマチ、変形性関節症、肝炎、気管支喘息、綿維症、糖尿病、動脈硬化、多発性硬化症、炎症性腸疾患(潰瘍性大腸炎、クローン病))、感染症(例えば肝炎)、自己免疫疾患(例えば全身性エリテマトーデス、多発性筋炎、自己免疫性甲状腺疾患、尿細管間質性腎炎、重症筋無力症)および骨疾患(例えば骨粗鬆症)等の治療剤(therapeutic agent)または予防剤(prophylactic agent)として用いることができる。
本発明のモノクローナル抗体を含有してなる医薬組成物は、炎症性疾患、例えばリウマチ関節炎、肝炎、気管支喘息、線維症、糖尿病、癌転移、動脈硬化、多発性硬化症、肉芽腫等の診断剤、また臓器移植後の慢性拒絶反応抑制、全身性自己免疫疾患・エリテマトーデス・ぶどう膜炎・ベーチェト病・多発性筋炎・糸状体増殖性腎炎・サルコイドーシス等の自己免疫疾患の診断剤として用いることができる。本発明のモノクローナル抗体は、α9インテグリンを特異的に認識することができるので、被検液中のα9インテグリンの定量、特にサンドイッチ免疫測定法、競合法、あるいはイムノメトリック法などによる定量などに使用することができる。これら個々の免疫学的測定法を本発明の測定方法に適用するにあたっては、特別の条件、操作等の設定は必要としない。それぞれの方法における通常の条件、操作法に当業者の通常の技術的配慮を加えて測定系を構築すればよい。これらの一般的な技術手段の詳細については、総説、成書などを参照することができる。
本発明の抗体が認識するヒトα9インテグリン上のエピトープを利用して、ヒトα9インテグリンの活性を阻害する化合物をスクリーニングすることができる。具体的には、本発明は、ヒトα9インテグリンのアミノ酸配列を含有するペプチド(以下、「ペプチドA」という)を用いることを特徴とする、ヒトα9インテグリンの活性を阻害する低分子化合物のスクリーニング方法を提供する。
[ヒトα9インテグリンに対する抗体の作製]
ヒトα9インテグリンに対する抗体作製は、以下のようにしてBALB/cマウス3匹に対して免疫を行った。まず、ヒトα9インテグリン発現細胞(ヒトα9/NIH-3T3細胞)を3×106細胞/匹を腹腔内投与し、さらにその1週間後と2週間後に、ヒトα9/NIH-3T3細胞を3×106細胞/匹を腹腔内投与した。さらに一週間後、ヒトα9/NIH-3T3細胞を2×106細胞/匹を静脈内投与した。ヒトα9/CHO-K1細胞及びヒトα9インテグリンを内在的に発現するヒトメラノーマ細胞株(G361細胞)に反応し、且つ、ヒトα4インテグリン発現CHO-K1細胞に反応しないクローンを抗α9インテグリン抗体とした。その結果、抗ヒトα9インテグリン抗体を産生するハイブリドーマ細胞2クローン(K33N、M35A)を樹立した。
[抗ヒトα9インテグリン抗体の相補認識領域(CDR)の解析]
ヒトα9インテグリン抗体(K33N、M35A)を産生するハイブリドーマからmRNAを抽出して、逆転写によってcDNAを作製した。このcDNAを鋳型とし、ScFvクローニング用プライマー(Light Primer Mix、Heavy Primer Mix;アマシャムバイオサイエンス社)を用いてPCRを行い、抗体の重鎖と軽鎖の可変領域をそれぞれ伸長・増幅した。次に、PCR産物を常法に基づいてpCRII TOPO vectorに組み込んだ。これをシークエンスしてアミノ酸配列を決定した。各抗体について3回ずつ上記の操作を行った。
[CDRH1]
K33N: SYYMN(配列番号1)
M35A: SYWIH(配列番号2)
[CDRH2]
K33N: WIFPGSGNTKYNEKFKGK(配列番号3)
M35A: EINPSSGRTNFIENFETK(配列番号4)
[CDRH3]
K33N: SWVSYERGYYFDY(配列番号5)
M35A: LAYGNYSWFAY(配列番号6)
[CDRL1]
K33N: RASENIYYSLA(配列番号7)
M35A: RASETVDSYGNTFMH(配列番号8)
[CDRL2]
K33N: NANSLED(配列番号9)
M35A: LASNLES(配列番号10)
[CDRL3]
K33N: KQAYDVPYT(配列番号11)
M35A: QQNNEDPYT(配列番号12)
ハイブリドーマ細胞(K33N)を10%牛胎児血清(FBS;HyClone)含有TIL Media I培地(免疫生物研究所)で7.5%CO2、37℃で培養し、増殖させた。 全RNAは、Invitrogenのプロトコールに従い、TRIzol試薬(Invitrogen)を用い、約3×106個のハイブリドーマ細胞から抽出した。 オリゴdT-プライマーを使用した逆転写反応でのcDNAの作製は、GeneRacer Kit(Invitrogen)を用い、Invitrogenのプロトコールに従った。H鎖とL鎖の可変領域cDNAは、マウス定常領域γ1とκにそれぞれ相当する3’ primerおよびGeneRacer Kit 添付のGeneRacer 5’ primer(5’-CGACTGGAGCACGAGGACACTGA-3’(配列番号14))を用い、Phusion DNA polymerase(New England Biolabs)を使用し、PCRで増幅した。 H鎖可変領域(VH)のPCR増幅のための3’ primaerは 5’-GCCAGTGGATAGACAGATGG-3’(配列番号15)である。L鎖可変領域(VL)のPCR増幅のための3’ primerは、5’-GATGGATACAGTTGGTGCAGC-3’(配列番号16)である。増幅したVHとVLの cDNAは配列決定のためにpCR4Blunt-TOPO vector(Invitrogen)中でサブクローニングした。可変領域のDNA配列解析はTocore(Menlo Park)で行った。
ハイブリドーマ細胞(M35A)を培養、増殖させた後、細胞の全RNAはRNAiso(タカラバイオ社)を用いて、Acid Guanidine-Phenol-Chloroform法(AGPC法)で抽出した。抽出したRNAは常法によりDNase I 処理を行った後、フェノールクロロホルム処理を行い、DNase I を除き、エタノール沈殿で精製した。得られたRNA は再度蒸留水に懸濁して解析に用いた。DNase I 処理後の RNA 約1μg を鋳型に、Random Primer(9mer)を用いて逆転写酵素Reverse Transcriptase M-MLV(RNase H free)で逆転写反応を行った。可変領域のPCR 増幅には、各逆転写反応液の一部を鋳型とし、H 鎖はプライマーHeavy Primer 1 とHeavy Primer 2(アマシャムバイオサイエンス社)を、L 鎖にプライマーLight Primer Mix(アマシャムバイオサイエンス社)をそれぞれ用い、PCR 酵素にはタカラTaKaRa LA Taq を使用した。
[抗ヒトα9インテグリン抗体の細胞接着阻害効果]
細胞接着する際にはα9インテグリンがOPN、ファイブロネクチン、テネイシンC、VCAM-1などの細胞外マトリックス(ECM)を含むリガンドと結合することから、得られた新規な抗ヒトα9インテグリン抗体の細胞接着阻害をα9インテグリン発現細胞(ヒトメラノーマ細胞G361)とリガンドの結合阻害で検討した。
[抗ヒトα9インテグリン抗体の認識部位の差異]
新規に作製した抗ヒトα9インテグリン抗体K33Nの細胞接着阻害効果がY9A2と同様な挙動を示したので、ヒトα9インテグリン発現細胞(hα9/CHO)に対する両抗体の競合反応をFACSで検出することにより、認識部位の差異を調べた。
Claims (18)
- 配列番号1~12のうちのいずれかのアミノ酸配列を含有する、抗ヒトα9インテグリン抗体。
- 配列番号1、3、5、7、9、または11のアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
- 配列番号1、3、5、7、9、および11のアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
- 配列番号2、4、6、8、10、または12のアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
- 配列番号2、4、6、8、10、および12のアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
- 重鎖の相補性決定領域(CDRH)におけるアミノ酸配列として配列番号1~6のいずれかのアミノ酸配列を、軽鎖の相補性決定領域(CDRL)におけるアミノ酸配列として配列番号7~12のいずれかのアミノ酸配列を含有する抗ヒトα9インテグリン抗体。
- ヒトα9インテグリンと、α9インテグリンのリガンドとの結合を阻害する、請求項1~6のいずれかに記載の抗ヒトα9インテグリン抗体。
- モノクローナル抗体である、請求項1~7のいずれかに記載の抗ヒトα9インテグリン抗体。
- キメラ抗体である、請求項1~8のいずれかに記載の抗ヒトα9インテグリン抗体。
- ヒト化抗体である、請求項1~8のいずれかに記載の抗ヒトα9インテグリン抗体。
- ヒト抗体である、請求項1~8のいずれかに記載の抗ヒトα9インテグリン抗体。
- 受託番号FERM BP-10830またはFERM BP-10831で標示されるハイブリドーマ細胞により産生される抗ヒトα9インテグリン抗体。
- 請求項1~12のいずれかに記載の抗ヒトα9インテグリン抗体を有効成分として含む、癌、炎症性疾患、感染症、自己免疫疾患または骨疾患の治療剤。
- 請求項1~12のいずれかに記載の抗ヒトα9インテグリン抗体および抗ヒトα4インテグリン抗体の両方を有効成分として含む、癌、炎症性疾患、感染症、自己免疫疾患または骨疾患の治療剤。
- 請求項1~12のいずれかに記載の抗ヒトα9インテグリン抗体を有効成分として含む、癌、炎症性疾患、感染症、自己免疫疾患または骨疾患の診断剤。
- 請求項1~12のいずれかに記載の抗ヒトαインテグリン抗体を産生する細胞。
- 受託番号FERM BP-10830またはFERM BP-10831で標示されるハイブリドーマ細胞。
- α9インテグリンのアミノ酸配列を含有するペプチドを用いることを特徴とする、α9インテグリンの活性を阻害する化合物のスクリーニング方法。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020117021763A KR101599096B1 (ko) | 2009-02-23 | 2009-02-23 | 항인간 α9 인테그린 항체와 그 용도 |
US13/138,470 US8372639B2 (en) | 2009-02-23 | 2009-02-23 | Anti-human α9 integrin antibody and use thereof |
PCT/JP2009/053218 WO2010095270A1 (ja) | 2009-02-23 | 2009-02-23 | 抗ヒトα9インテグリン抗体とその用途 |
AU2009340658A AU2009340658B2 (en) | 2009-02-23 | 2009-02-23 | Anti-human alpha9 integrin antibody and use thereof |
CA2753280A CA2753280C (en) | 2009-02-23 | 2009-02-23 | Anti-human .alpha.9 integrin antibody and use thereof |
EP09840376.9A EP2399937B1 (en) | 2009-02-23 | 2009-02-23 | Anti-human alpha9 integrin antibody and use thereof |
CN200980157346.XA CN102325796B (zh) | 2009-02-23 | 2009-02-23 | 抗人α9整合素抗体及其用途 |
US13/742,680 US9040295B2 (en) | 2009-02-23 | 2013-01-16 | Anti-human α9 integrin antibody and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2009/053218 WO2010095270A1 (ja) | 2009-02-23 | 2009-02-23 | 抗ヒトα9インテグリン抗体とその用途 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/138,470 A-371-Of-International US8372639B2 (en) | 2009-02-23 | 2009-02-23 | Anti-human α9 integrin antibody and use thereof |
US13/742,680 Continuation US9040295B2 (en) | 2009-02-23 | 2013-01-16 | Anti-human α9 integrin antibody and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010095270A1 true WO2010095270A1 (ja) | 2010-08-26 |
Family
ID=42633570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/053218 WO2010095270A1 (ja) | 2009-02-23 | 2009-02-23 | 抗ヒトα9インテグリン抗体とその用途 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8372639B2 (ja) |
EP (1) | EP2399937B1 (ja) |
KR (1) | KR101599096B1 (ja) |
CN (1) | CN102325796B (ja) |
AU (1) | AU2009340658B2 (ja) |
CA (1) | CA2753280C (ja) |
WO (1) | WO2010095270A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012028622A3 (en) * | 2010-08-31 | 2012-07-05 | Sanofi | Peptide or peptide complex binding to 2 integrin and methods and uses involving the same |
WO2013001819A1 (ja) * | 2011-06-30 | 2013-01-03 | 株式会社免疫生物研究所 | 可溶性インテグリンα4変異体 |
AU2010221993B2 (en) * | 2009-03-10 | 2015-01-15 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized K33N monoclonal antibody |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0546073A1 (en) | 1990-08-29 | 1993-06-16 | Genpharm Int | NON-HUMAN TRANSGENETES CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
WO2002081522A1 (fr) | 2001-04-05 | 2002-10-17 | Immuno-Biological Laboratories Co., Ltd. | Anticorps dirigé contre l'ostéopontine, et son utilisation |
WO2006075784A1 (ja) * | 2005-01-13 | 2006-07-20 | Gene Techno Science Co., Ltd. | 抗α9インテグリン抗体とその用途 |
WO2008007804A1 (fr) * | 2006-07-12 | 2008-01-17 | Gene Techno Science Co., Ltd. | ANTICORPS ANTI-INTÉGRINE α-9 HUMAINE ET UTILISATION DE CELUI-CI |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2003027151A1 (ja) | 2001-09-25 | 2005-01-06 | 株式会社 免疫生物研究所 | 組換え抗オステオポンチン抗体およびその用途 |
WO2008081522A1 (ja) | 2006-12-27 | 2008-07-10 | Pioneer Corporation | 移動体用楽曲情報処理装置、および移動体用楽曲情報処理方法 |
WO2009084671A1 (ja) * | 2007-12-28 | 2009-07-09 | Astellas Pharma Inc. | ヒト抗α9インテグリン抗体 |
-
2009
- 2009-02-23 CA CA2753280A patent/CA2753280C/en active Active
- 2009-02-23 WO PCT/JP2009/053218 patent/WO2010095270A1/ja active Application Filing
- 2009-02-23 KR KR1020117021763A patent/KR101599096B1/ko active IP Right Grant
- 2009-02-23 AU AU2009340658A patent/AU2009340658B2/en active Active
- 2009-02-23 US US13/138,470 patent/US8372639B2/en active Active
- 2009-02-23 EP EP09840376.9A patent/EP2399937B1/en active Active
- 2009-02-23 CN CN200980157346.XA patent/CN102325796B/zh active Active
-
2013
- 2013-01-16 US US13/742,680 patent/US9040295B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0546073A1 (en) | 1990-08-29 | 1993-06-16 | Genpharm Int | NON-HUMAN TRANSGENETES CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
WO2002081522A1 (fr) | 2001-04-05 | 2002-10-17 | Immuno-Biological Laboratories Co., Ltd. | Anticorps dirigé contre l'ostéopontine, et son utilisation |
WO2006075784A1 (ja) * | 2005-01-13 | 2006-07-20 | Gene Techno Science Co., Ltd. | 抗α9インテグリン抗体とその用途 |
WO2008007804A1 (fr) * | 2006-07-12 | 2008-01-17 | Gene Techno Science Co., Ltd. | ANTICORPS ANTI-INTÉGRINE α-9 HUMAINE ET UTILISATION DE CELUI-CI |
Non-Patent Citations (4)
Title |
---|
A.WANG, AM. J. RESPIR.,CELL MOL. BIOL., vol. 15, 1996, pages 664 - 672 |
ED HARLOW, DAVID LANE: "Antibodies: A Laboratory Manual.", 1988, COLD SPRING HARBOR LABORATORY |
See also references of EP2399937A4 * |
WANG ANGELA. ET AL.: "Differential Regulation of Airway Epithelial Integrins by Growth Factors", AM. J. RESPIR. CELL MOL. BIOL., vol. 15, 1996, pages 664 - 672, XP002915231 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010221993B2 (en) * | 2009-03-10 | 2015-01-15 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized K33N monoclonal antibody |
AU2010221993C1 (en) * | 2009-03-10 | 2015-07-09 | Gene Techno Science Co., Ltd. | Generation, expression and characterization of the humanized K33N monoclonal antibody |
WO2012028622A3 (en) * | 2010-08-31 | 2012-07-05 | Sanofi | Peptide or peptide complex binding to 2 integrin and methods and uses involving the same |
US9234039B2 (en) | 2010-08-31 | 2016-01-12 | Sanofi | Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same |
WO2013001819A1 (ja) * | 2011-06-30 | 2013-01-03 | 株式会社免疫生物研究所 | 可溶性インテグリンα4変異体 |
EP2727937A1 (en) * | 2011-06-30 | 2014-05-07 | Immuno-Biological Laboratories Co., Ltd. | Soluble integrin 4 mutant |
EP2727937A4 (en) * | 2011-06-30 | 2015-03-18 | Immuno Biological Lab Co Ltd | SOLUBLE MUTANT OF INEGRINE ALPHA-4 |
Also Published As
Publication number | Publication date |
---|---|
AU2009340658B2 (en) | 2015-02-26 |
CN102325796B (zh) | 2014-07-16 |
US20130122019A1 (en) | 2013-05-16 |
CN102325796A (zh) | 2012-01-18 |
US8372639B2 (en) | 2013-02-12 |
CA2753280A1 (en) | 2010-08-26 |
US20110318368A1 (en) | 2011-12-29 |
EP2399937B1 (en) | 2016-04-27 |
US9040295B2 (en) | 2015-05-26 |
AU2009340658A1 (en) | 2011-09-22 |
KR101599096B1 (ko) | 2016-03-02 |
EP2399937A9 (en) | 2013-10-16 |
KR20110122851A (ko) | 2011-11-11 |
EP2399937A1 (en) | 2011-12-28 |
EP2399937A4 (en) | 2013-08-28 |
CA2753280C (en) | 2017-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4871740B2 (ja) | 抗α9インテグリン抗体とその用途 | |
JP5066087B2 (ja) | 抗ヒトα9インテグリン抗体とその用途 | |
WO2009101968A1 (ja) | 抗adam-15抗体及びその利用 | |
US9040295B2 (en) | Anti-human α9 integrin antibody and use thereof | |
JP5781504B2 (ja) | 細胞外マトリックスタンパク質のアミノ酸配列rgdに特異的なヒト化抗体およびそれらの使用 | |
EP2075258B1 (en) | Antibody against rgd in amino acid sequence of extracellular matrix protein and production method and use of the same | |
JP5306659B2 (ja) | 抗ヒトα9インテグリン抗体とその用途 | |
JP5687305B2 (ja) | 抗ヒトα9インテグリン抗体とその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980157346.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09840376 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2753280 Country of ref document: CA Ref document number: 13138470 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009340658 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009840376 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117021763 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6768/CHENP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009340658 Country of ref document: AU Date of ref document: 20090223 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: JP |